Abstract
Monitoring of adverse events following the administration of MMR vaccine containing the Urabe mumps virus vaccine strain, to over 2 million schoolchildren (aged 6-13 years) revealed that the incidence of vaccine-associated aseptic meningitis was one case per 295 000 doses given. About 92 per cent of these children had had their primary immunization against MMR at 12 months of age and, therefore, were probably not immunologically naïve. It appears from our data that the use of the Urabe-based mumps vaccine in the booster-dose format induces much less adverse effects than usually observed following the primary immunization with it. Further studies are needed to prove this conclusively.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
